Why It Matters
Bristol-Myers Squibb Co. has hired Alexander J. Beckles LLC to represent its interests on health policy matters, according to a new lobbying disclosure filed Monday, June 29. The pharmaceutical giant's move to engage external lobbying counsel marks a significant pivot as the company faces mounting pressure over drug pricing practices.
The company raised the price of its cancer drug Opdivo by 4% to $260,000 since President Donald Trump took office in January 2025, a decision that drew public criticism from lawmakers. The firm is now among other pharmaceutical companies that have signed "Most Favored Nation" deals with the Trump Administration, positioning itself within a broader industry landscape shaped by new pricing pressures.
Broader Context
Alex Beckles is listed as the sole lobbyist on the Bristol-Myers Squibb engagement. Beckles brings substantial Capitol Hill experience to the role, having served as a congressional lobbyist for approximately seven years and 10 months during the 106th through 110th Congresses, where he worked as Senior Legislative Assistant to former Rep. Edolphus Towns (D-NY-10).
Bristol-Myers Squibb's lobbying disclosure arrives amid ongoing congressional debate over medical pricing. The company's engagement with external lobbying counsel suggests an effort to shape the conversation around drug pricing policy as Congress continues examining pharmaceutical industry practices.
The Bottom Line
Bristol-Myers Squibb's new lobbyist registration signals the company's intention to increase its direct engagement with Congress on health policy matters. With a former congressional staffer now representing the company's interests, the pharmaceutical manufacturer is positioning itself to address ongoing scrutiny of its pricing practices during a period of heightened regulatory and legislative attention.
Access the Legis1 platform for comprehensive political news, data, and insights.
Spot something wrong? Report an issue with this article